Rchr
J-GLOBAL ID:201301009478579550   Update date: Jul. 22, 2024

ODA Chigusa

オダ チグサ | ODA Chigusa
Affiliation and department:
Job title: Associate Professor
Research theme for competitive and other funds  (12):
  • 2023 - 2026 免疫受容体制御による新たな急性脊髄損傷治療体系の確立
  • 2022 - 2024 虚血再灌流後の臓器機能不全を予防する新規免疫学的アプローチの基盤開発
  • 2019 - 2021 Proposal of a novel therapeutic concept for cerebral ischemic disease by regulation of efferocytosis
  • 2018 - 2019 死細胞の貪食を制御する機構の解明
  • 2016 - 2019 Elucidation of the regulatory mechanism of allergic disease via commensal microbiota and regulatory T cells
Show all
Papers (57):
  • Koizumi, Hitoshi, Nakahashi-Oda, Chigusa, Lyu W, Yamashita-Kanemaru, Yumi, Tabuchi, Keiji, Shibuya, Kazuko, Shibuya, Akira. Development of monoclonal antibodies specific to either CD300AR111 or CD300AQ111 or both. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2023. 42. 5. 182-185
  • 小泉仁志, 小田, ちぐさ, 渋谷彰. CD300a阻害による脳梗塞後の神経障害の軽減. Journal of Clinical and Experimental Medicine. 2023. 284. 11. 892-893
  • Miyashita, Daisuke, Inoue, Ryota, Tsuno, Takahiro, Okuyama, Tomoko, Kyohara, Mayu, Nakahashi-Oda, Chigusa, Nishiyama, Kuniyuki, Fukushima, Setsuko, Inada, Yutaro, Togashi, Yu, et al. Protective effects of S100A8 on sepsis mortality: Links to sepsis risk in obesity and diabetes. iScience. 2022. 25. 12
  • Nishiyama, Nanako, Nakahashi-Oda, Chigusa, Shibuya, Akira. Interferon-beta promotes the survival and function of induced regulatory T cells. Cytokine. 2022. 158
  • Yuta Nakazawa, Nanako Nishiyama, Hitoshi Koizumi, Kazumasa Kanemaru, Chigusa Nakahashi-Oda, Akira Shibuya. Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. eLife. 2021. 10
more...
MISC (3):
  • 小田 ちぐさ, 中橋, 田原 聡子, 安居 輝人, 菊谷 仁, 本多 伸一郎, 渋谷 和子, 長田 重一, 渋谷 彰. 炎症/病態 アポトーシス細胞と肥満細胞上のCD300aによる炎症応答の調節(Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor). 日本免疫学会総会・学術集会記録. 2011. 40. 232-232
  • Activating immune receptor MAIR-2 associates with DAP12 and FcRγ chain on peritoneal macrophages. Clinical immunology & allergology. 2010. 54. 2. 142-148
  • Activating immune receptor MAIR-2 associates with DAP12 and FcRγ chain on peritoneal macrophages. Clinical immunology & allergology. 2009. 52. 1. 26-33
Patents (13):
  • ACTIVITY MODULATOR, MEDICINAL AGENT COMPRISING SAME, USE OF CD300A GENE-DEFICIENT MOUSE, AND ANTI-CD300A ANTIBODY
  • Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
  • アレルギー疾患に関する、CD300a発現細胞の活性調節剤を含有する医薬品、ならびにCD300a遺伝子欠損マウスおよびCD300a発現細胞の活性調節剤の使用
  • 活性調節剤
  • 活性調節剤、これを含有する医薬品、および抗CD300a抗体
more...
Lectures and oral presentations  (93):
  • CD300a immunoreceptor exacerbates heart injury and adverse remodeling after myocardial infarction and reperfusion in mice
    (第88回日本循環器学会学術集会)
  • CD300a immunoreceptor exacerbates acute kidney injury and fibrosis after renal ischemia and reperfusion in mice
    (第52回日本免疫学会学術集会)
  • CD300a immunoreceptor exacerbates heart injury and adverse remodeling after myocardial infarction and reperfusion in mice
    (第52回日本免疫学会学術集会)
  • The role of an immune-inhibitory receptor CD300a in kidney injury.
    (JSICR/MMCB 2023 Joint meeting)
  • CD300a exacerbates heart injury and adverse remodeling after myocardial infarction.
    (International Symposium on Immune Regulation)
more...
Professional career (1):
  • 博士(医学) (筑波大学)
Committee career (1):
  • - 現在 日本免疫学会 評議員
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page